PT - JOURNAL ARTICLE AU - Dobson, Ruth AU - Patterson, Katherine AU - Malik, Reshad AU - Mandal, Uttara AU - Asif, Hina AU - Humphreys, Ros AU - Payne, Michael AU - O-Charoenrat, Eng AU - Huzzey, Lauren AU - Clare, Adam AU - Green, Kate AU - Morton, Maija AU - Sohrabi, Catrin AU - Singh, Navreen AU - Pasupathy, Amirtha AU - Patel, Milan AU - Whiteman, Sam AU - Maxmin, Kate AU - Bass, Nicholas AU - Gupta, Bhavya AU - Cooper, Claudia AU - Marshall, Charles AU - Weil, Rimona Sharon AU - Mummery, Catherine J TI - Eligibility for antiamyloid treatment: preparing for disease-modifying therapies for Alzheimer’s disease AID - 10.1136/jnnp-2024-333468 DP - 2024 Sep 01 TA - Journal of Neurology, Neurosurgery & Psychiatry PG - 796--803 VI - 95 IP - 9 4099 - http://jnnp.bmj.com/content/95/9/796.short 4100 - http://jnnp.bmj.com/content/95/9/796.full SO - J Neurol Neurosurg Psychiatry2024 Sep 01; 95 AB - Background Disease-modifying therapies (DMTs) for Alzheimer’s disease (AD) have early evidence of efficacy. Widespread delivery of DMTs will require major service reconfiguration. Treatment pathways will need to include triaging for eligibility, regular infusions and baseline and follow-up MRI scanning. A critical step in planning is provision of real-world estimates of patients likely to be eligible for triaging, but these are challenging to obtain.Methods We performed a retrospective service evaluation of patients attending five memory services across North and East London and a national specialist cognitive disorders service. We examined the likely proportion of patients who would (1) be referred for triaging for DMTs and (2) potentially be suitable for treatments.Results Data from a total of 1017 patients were included, 517 of whom were seen in community memory services and 500 in a specialist clinic. In the memory services, 367/517 (71%) were diagnosed with possible AD. After exclusions of those in whom cognitive and frailty scores, MRI contraindications or anticoagulant use indicated they would be unlikely to be suitable, an estimated 32% would be eligible for triaging. In the specialist cognitive clinic, where additional investigations are available, 14% of those seen (70/500) would be potentially eligible for treatment.Conclusions While a sizeable proportion of patients attending memory clinics may be referred for triaging for DMTs for AD, only a minority are likely to be suitable for these, as demonstrated in patients seen in specialist cognitive services. This will need to be considered when designing pathways for DMT delivery.